Trial Profile
Randomized Phase 3 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Dec 2021
Price :
$35
*
At a glance
- Drugs Iniparib (Primary) ; Carboplatin; Gemcitabine
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms ECLIPSE
- Sponsors Sanofi
- 18 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database
- 03 Jun 2013 Primary endpoint 'Overall-survival-rate' has not been met, according to a Sanofi media release.
- 03 Jun 2013 Status changed from active, no longer recruiting to completed.